CNPY2

Summary

CNPY2 (canopy FGF signaling regulator 2, HGNC:13529) is a protein-coding gene on chromosome 12q13.3, encoding Protein canopy homolog 2 (Q9Y2B0). Positive regulator of neurite outgrowth by stabilizing myosin regulatory light chain (MRLC). It is a selective cancer dependency (DepMap: 10.8% of cell lines).

Predicted to be active in endoplasmic reticulum.

Source: NCBI Gene 10330 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 36 total — 1 likely-pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 10.8% of screened cell lines
• MANE Select transcript: NM_014255

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13529
Approved symbol	CNPY2
Name	canopy FGF signaling regulator 2
Location	12q13.3
Locus type	gene with protein product
Status	Approved
Aliases	HP10390, ZSIG9
Ensembl gene	ENSG00000257727
Ensembl biotype	protein_coding
OMIM	605861
Entrez	10330

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 13 protein_coding, 5 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000273308, ENST00000546388, ENST00000546466, ENST00000546937, ENST00000547570, ENST00000548013, ENST00000551276, ENST00000551286, ENST00000551475, ENST00000551720, ENST00000553164, ENST00000553191, ENST00000929941, ENST00000929942, ENST00000929943, ENST00000929944, ENST00000929945, ENST00000929946, ENST00000929947, ENST00000929948, ENST00000971705, ENST00000971706

RefSeq mRNA: 2 — MANE Select: NM_014255 NM_001190991, NM_014255

CCDS: CCDS8914

Canonical transcript exons

ENST00000273308 — 6 exons

Exon	Start	End
ENSE00001182210	56315821	56315988
ENSE00003492315	56315130	56315242
ENSE00003508337	56309844	56310595
ENSE00003549965	56311211	56311414
ENSE00003612430	56314851	56314966
ENSE00003786464	56310958	56311054

Expression profiles

Bgee: expression breadth ubiquitous, 290 present calls, max score 98.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 83.1399 / max 706.0477, expressed in 1824 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
131510	30.6878	1813
131509	25.2303	1812
131508	15.9393	1799
131507	9.5951	1750
131512	1.2370	806
131506	0.3576	160
131513	0.0928	21

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	98.81	gold quality
stromal cell of endometrium	CL:0002255	98.49	gold quality
pituitary gland	UBERON:0000007	98.44	gold quality
body of pancreas	UBERON:0001150	98.35	gold quality
right lobe of thyroid gland	UBERON:0001119	98.00	gold quality
right adrenal gland cortex	UBERON:0035827	97.89	gold quality
left adrenal gland	UBERON:0001234	97.88	gold quality
left adrenal gland cortex	UBERON:0035825	97.88	gold quality
left lobe of thyroid gland	UBERON:0001120	97.86	gold quality
right adrenal gland	UBERON:0001233	97.84	gold quality
right lobe of liver	UBERON:0001114	97.77	gold quality
adrenal cortex	UBERON:0001235	97.63	gold quality
right ovary	UBERON:0002118	97.63	gold quality
mucosa of transverse colon	UBERON:0004991	97.61	gold quality
minor salivary gland	UBERON:0001830	97.60	gold quality
rectum	UBERON:0001052	97.51	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.47	gold quality
body of stomach	UBERON:0001161	97.43	gold quality
left ovary	UBERON:0002119	97.39	gold quality
islet of Langerhans	UBERON:0000006	97.29	gold quality
thyroid gland	UBERON:0002046	97.28	gold quality
thoracic aorta	UBERON:0001515	97.26	gold quality
ascending aorta	UBERON:0001496	97.25	gold quality
endocervix	UBERON:0000458	97.24	gold quality
pancreas	UBERON:0001264	97.22	gold quality
right uterine tube	UBERON:0001302	97.22	gold quality
descending thoracic aorta	UBERON:0002345	97.22	gold quality
left coronary artery	UBERON:0001626	97.21	gold quality
tibial nerve	UBERON:0001323	97.14	gold quality
metanephros cortex	UBERON:0010533	97.10	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	23.54
E-MTAB-7606	no	648.26
E-HCAD-31	no	20.58

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
MYLIP	Repression

miRNA regulators (miRDB)

23 targeting CNPY2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-6826-3P	98.19	66.32	1153
HSA-MIR-637	97.91	64.05	1517
HSA-MIR-6835-5P	95.81	64.27	500

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 10.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 14)

• MSAP is a novel MIR-interacting protein that enhances neurite outgrowth and increases myosin regulatory light chain in fetal and adult brain. (PMID:12826659)
• Our results are consistent with an important role of FGF21 and Cnpy2/Msap in the regulation of LDLRs in cultured cells. (PMID:22378787)
• CNPY2 is a HIF-1alpha-regulated, secreted angiogenic growth factor that promotes smooth muscle cell migration, proliferation, and tissue revascularization. (PMID:25589425)
• CNPY2 may play a critical role in colorectal cancer development by enhancing cell proliferation, migration, and angiogenesis and by inhibiting apoptosis through negative regulation of the p53 pathway (PMID:26835537)
• These findings suggested that CNPY2 promoted cancer cell growth in renal cell carcinoma cells through regulating TP53 gene expression. (PMID:28235487)
• CNPY2 isoform2 represents as a novel and valuable prognostic indicator for colorectal cancer patients. (PMID:29135454)
• Overexpression of CNPY2 can activate the AKT/GSK3beta pathway, which leads to the inactivation of GSK-3beta. The inactivation of GSK-3beta increases the level of Snail, and then decreases the expression of E-cadherin to promote EMT. (PMID:29569784)
• CNPY2 can serve as a therapeutic target to promote the effect of chemotherapy in non-small cell lung cancer. (PMID:29864955)
• This study showed that serum CNPY2 isoform 2 may be a valuable biomarker for the early detection of colorectal cancer and presents an improvement in the diagnostic efficiency by combination of CEA and CA19-9. (PMID:30070972)
• CNPY2 knockout resulted in the significant suppression of MHCC97H cell proliferation, tumor growth, and hemorrhage. (PMID:30415246)
• Knockout of Cnpy2 resulted in up-regulation of p16(INK4a). (PMID:31047986)
• miR30a3p suppresses the proliferation and migration of lung adenocarcinoma cells by downregulating CNPY2. (PMID:31894275)
• Sleeping Beauty insertional mutagenesis screen identifies the pro-metastatic roles of CNPY2 and ACTN2 in hepatocellular carcinoma tumor progression. (PMID:33482578)
• Hypoxia-induced CNPY2 upregulation promotes glycolysis in cervical cancer through activation of AKT pathway. (PMID:33721832)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cnpy2	ENSMUSG00000025381
rattus_norvegicus	Cnpy2	ENSRNOG00000003549
drosophila_melanogaster	sel	FBGN0263260
caenorhabditis_elegans	Y47H9C.8	WBGENE00012951
caenorhabditis_elegans		WBGENE00017165
caenorhabditis_elegans		WBGENE00017169

Paralogs (2): CNPY1 (ENSG00000146910), (ENSG00000283128)

Protein

Protein identifiers

Protein canopy homolog 2 — Q9Y2B0 (reviewed: Q9Y2B0)

Alternative names: MIR-interacting saposin-like protein, Putative secreted protein Zsig9, Transmembrane protein 4

All UniProt accessions (5): Q9Y2B0, F8VXJ7, F8W1K5, H0YI18, H0YIH9

UniProt curated annotations — full annotation on UniProt →

Function. Positive regulator of neurite outgrowth by stabilizing myosin regulatory light chain (MRLC). It prevents MIR-mediated MRLC ubiquitination and its subsequent proteasomal degradation.

Subunit / interactions. Interacts with MYLIP/MIR.

Subcellular location. Endoplasmic reticulum.

Tissue specificity. Expressed in different tissues. Highest levels are detected in adult placenta, liver and pancreas.

Similarity. Belongs to the canopy family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y2B0-1	1	yes
Q9Y2B0-2	2

RefSeq proteins (1): NP_055070* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008139	SaposinB_dom	Domain
IPR021852	DUF3456	Domain
IPR042415	CNPY	Family

Pfam: PF11938

UniProt features (10 total): disulfide bond 3, splice variant 2, signal peptide 1, chain 1, domain 1, short sequence motif 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y2B0-F1	84.95	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 115

Disulfide bonds (3): 28–171, 31–164, 86–137

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 153 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, MODULE_151, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, BOYAULT_LIVER_CANCER_SUBCLASS_G2, MEF2_02, GOBP_LOW_DENSITY_LIPOPROTEIN_PARTICLE_CLEARANCE, GOBP_PLASMA_LIPOPROTEIN_PARTICLE_CLEARANCE, MORF_ATOX1, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, MORF_PPP2R4, GARY_CD5_TARGETS_DN, AFP1_Q6, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_REGULATION_OF_PLASMA_LIPOPROTEIN_PARTICLE_LEVELS, TIEN_INTESTINE_PROBIOTICS_24HR_UP

GO Biological Process (2): negative regulation of gene expression (GO:0010629), regulation of low-density lipoprotein particle clearance (GO:0010988)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
gene expression	1
regulation of gene expression	1
negative regulation of macromolecule biosynthetic process	1
regulation of lipoprotein particle clearance	1
low-density lipoprotein particle clearance	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

712 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CNPY2	MYL11	Q96A32	883
CNPY2	PSAPL1	Q6NUJ1	859
CNPY2	LRRTM4	Q86VH4	854
CNPY2	MYLIP	Q8WY64	848
CNPY2	MYL12B	O14950	827
CNPY2	PSAP	P07292	748
CNPY2	CNPY4	Q8N129	644
CNPY2	CNPY3	Q9BT09	577
CNPY2	PTPRS	Q13332	535
CNPY2	LRRTM1	Q86UE6	497
CNPY2	XPR1	Q9UBH6	497
CNPY2	HSPA5	P11021	472
CNPY2	GPC4	O75487	430
CNPY2	NGF	P01138	430
CNPY2	PLAU	P00749	424

IntAct

34 interactions, top by confidence:

A	B	Type	Score
ADRA2C	CNPY2	psi-mi:“MI:0915”(physical association)	0.560
CNPY2	MYLIP	psi-mi:“MI:0915”(physical association)	0.510
MYLIP	CNPY2	psi-mi:“MI:0915”(physical association)	0.510
COL1A1	GOLIM4	psi-mi:“MI:0914”(association)	0.500
	CNPY2	psi-mi:“MI:0407”(direct interaction)	0.410
CNPY2	TRIM28	psi-mi:“MI:0915”(physical association)	0.400
CNPY2	HSP90B1	psi-mi:“MI:0915”(physical association)	0.400
CNPY2	ECE1	psi-mi:“MI:0915”(physical association)	0.370
ECE1	CNPY2	psi-mi:“MI:0915”(physical association)	0.370
KSR1	FBLL1	psi-mi:“MI:0914”(association)	0.350
BCK	NOL9	psi-mi:“MI:0914”(association)	0.350
CNPY2	COL2A1	psi-mi:“MI:0914”(association)	0.350
TRIM24	DDTL	psi-mi:“MI:0914”(association)	0.350
MAP3K7	ACOT7	psi-mi:“MI:0914”(association)	0.350
RIPK4	TBCA	psi-mi:“MI:0914”(association)	0.350
MYLK4	AP3D1	psi-mi:“MI:0914”(association)	0.350
PDIA5	MBL2	psi-mi:“MI:0914”(association)	0.350
CNPY2	GBA1	psi-mi:“MI:0914”(association)	0.350
VENTX	UBA6	psi-mi:“MI:0914”(association)	0.350
GATA2	EFCAB5	psi-mi:“MI:0914”(association)	0.350
TCTN1	TOR1A	psi-mi:“MI:2364”(proximity)	0.270
TCTN1	PLOD2	psi-mi:“MI:2364”(proximity)	0.270
AXL	ILVBL	psi-mi:“MI:2364”(proximity)	0.270
EPHA10	PLOD2	psi-mi:“MI:2364”(proximity)	0.270
DDX6	RPSA2	psi-mi:“MI:2364”(proximity)	0.270
PINX1	CNPY2	psi-mi:“MI:0915”(physical association)	0.000
TNIK	CNPY2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (92): MAP1S (Co-fractionation), CNPY2 (Proximity Label-MS), KIF22 (Affinity Capture-MS), DLG3 (Affinity Capture-MS), VWA1 (Affinity Capture-MS), CTC1 (Affinity Capture-MS), PDIA5 (Affinity Capture-MS), FBXL4 (Affinity Capture-MS), COL2A1 (Affinity Capture-MS), OBFC1 (Affinity Capture-MS), GNB1L (Affinity Capture-MS), WDR45B (Affinity Capture-MS), CNPY2 (Affinity Capture-RNA), CNPY2 (Affinity Capture-MS), CNPY2 (Reconstituted Complex)

ESM2 similar proteins: A2BD09, A3KNS2, A5GFQ5, P15943, P24338, Q01580, Q06175, Q06186, Q06335, Q06481, Q08AE8, Q08DX0, Q09118, Q0P5N1, Q0VCT2, Q0VDN7, Q13438, Q2L6K8, Q3MHX6, Q3SWX1, Q58D79, Q58T08, Q5HZV5, Q5MJS3, Q5RKH6, Q68BL7, Q6GN40, Q701R2, Q86VZ4, Q8BHP7, Q8BQ47, Q8CB67, Q8CD91, Q8K2C7, Q8N129, Q8TEQ0, Q92563, Q96C34, Q96KC8, Q99075

Diamond homologs: Q2L6L1, Q3B7I2, Q4VAB4, Q5M7D4, Q7JXF7, Q9QXT0, Q9Y2B0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	29
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1679340	NM_014255.7(CNPY2):c.46_50del (p.Gly16fs)	Likely pathogenic

SpliceAI

1727 predictions. Top by Δscore:

Variant	Effect	Δscore
12:56309964:A:AC	donor_gain	1.0000
12:56309965:C:CC	donor_gain	1.0000
12:56310508:T:TA	donor_gain	1.0000
12:56311051:CACA:C	acceptor_gain	1.0000
12:56311053:CA:C	acceptor_gain	1.0000
12:56311055:C:CC	acceptor_gain	1.0000
12:56311064:C:CT	acceptor_gain	1.0000
12:56311064:C:T	acceptor_gain	1.0000
12:56311065:A:T	acceptor_gain	1.0000
12:56311206:CTCA:C	donor_loss	1.0000
12:56311208:CA:C	donor_loss	1.0000
12:56311209:A:AC	donor_gain	1.0000
12:56311209:A:AT	donor_loss	1.0000
12:56311210:C:CC	donor_gain	1.0000
12:56314846:GTTAC:G	donor_loss	1.0000
12:56314847:TTA:T	donor_loss	1.0000
12:56314847:TTACC:T	donor_loss	1.0000
12:56314848:TACCT:T	donor_loss	1.0000
12:56314849:A:T	donor_loss	1.0000
12:56314850:C:G	donor_loss	1.0000
12:56314850:CCTCC:C	donor_loss	1.0000
12:56314852:T:TA	donor_gain	1.0000
12:56314967:C:CC	acceptor_gain	1.0000
12:56315053:T:TA	donor_gain	1.0000
12:56315098:T:TA	donor_gain	1.0000
12:56315124:CTTTA:C	donor_loss	1.0000
12:56315125:TTTAC:T	donor_loss	1.0000
12:56315126:TTAC:T	donor_loss	1.0000
12:56315127:TACCT:T	donor_loss	1.0000
12:56315128:A:AT	donor_loss	1.0000

AlphaMissense

1186 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:56310972:C:G	C164S	1.000
12:56310973:A:T	C164S	1.000
12:56311362:C:T	C86Y	1.000
12:56311386:A:G	L78P	1.000
12:56310588:A:C	C171W	0.999
12:56310589:C:A	C171F	0.999
12:56310589:C:G	C171S	0.999
12:56310589:C:T	C171Y	0.999
12:56310590:A:G	C171R	0.999
12:56310590:A:T	C171S	0.999
12:56310971:G:C	C164W	0.999
12:56310972:C:T	C164Y	0.999
12:56310973:A:G	C164R	0.999
12:56311052:A:C	C137W	0.999
12:56311053:C:A	C137F	0.999
12:56311053:C:T	C137Y	0.999
12:56311054:A:G	C137R	0.999
12:56311344:T:C	Y92C	0.999
12:56311361:A:C	C86W	0.999
12:56311362:C:G	C86S	0.999
12:56311363:A:G	C86R	0.999
12:56311363:A:T	C86S	0.999
12:56311399:A:G	S74P	0.999
12:56314870:C:A	G62V	0.999
12:56314871:C:A	G62C	0.999
12:56314882:A:G	I58T	0.999
12:56314885:C:G	R57P	0.999
12:56314887:G:C	F56L	0.999
12:56314887:G:T	F56L	0.999
12:56314888:A:C	F56C	0.999

dbSNP variants (sampled 300 via entrez): RS1000664012 (12:56317908 G>A), RS1000680863 (12:56317021 G>A), RS1000807604 (12:56313446 T>C), RS1001056227 (12:56316740 G>A,T), RS1001494557 (12:56316635 C>T), RS1001649017 (12:56309709 A>G), RS1001826742 (12:56312562 ATTCTTTTTTTTT>A), RS1002828373 (12:56313169 C>T), RS1002833588 (12:56314153 T>C), RS1003694539 (12:56315405 G>A), RS1003831638 (12:56315184 C>A,G), RS1003924927 (12:56311003 G>A,T), RS1004060889 (12:56311315 G>A,T), RS1004234907 (12:56315690 C>G), RS1004526244 (12:56317522 A>C)

Disease associations

OMIM: gene MIM:605861 | disease phenotypes: MIM:123100

GenCC curated gene-disease

Mondo (1): craniosynostosis (MONDO:0015469)

Orphanet (1): Craniosynostosis (Orphanet:1531)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST003336_8	Waist circumference adjusted for body mass index	4.000000e-09
GCST008839_427	Height	1.000000e-189
GCST010002_217	Refractive error	6.000000e-174
GCST90090967_21	Height	1.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D003398	Craniosynostoses	C05.116.099.370.894.232; C05.660.207.240; C05.660.906.364; C16.131.621.207.240; C16.131.621.906.364

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067216 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.81	Kd	15.6	nM	CHEMBL5653589
7.61	ED50	24.84	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148100: Binding affinity to human CNPY2 incubated for 45 mins by Kinobead based pull down assay	kd	0.0156	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	affects cotreatment, increases expression	3
cobaltous chloride	decreases expression	2
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
Vorinostat	decreases expression, increases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
Valproic Acid	increases expression, affects expression	2
deoxynivalenol	decreases expression	1
methylselenic acid	decreases expression	1
nivalenol	increases expression	1
perfluorooctane sulfonic acid	increases expression	1
ICG 001	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
LDN 193189	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	increases abundance, affects expression	1
Atrazine	decreases expression	1
Catechin	decreases expression, affects cotreatment	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Ouabain	affects expression	1
Ozone	affects expression, increases abundance	1
Phenobarbital	affects expression	1
Selenium	decreases expression	1
Smoke	decreases expression	1
Thimerosal	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651142	Binding	Binding affinity to human CNPY2 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2UP	Abcam HEK293T CNPY2 KO	Transformed cell line	Female

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00722436	PHASE4	TERMINATED	Tranexamic Acid for Craniofacial Surgery
NCT02188576	PHASE4	COMPLETED	The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery
NCT02229968	PHASE2	ACTIVE_NOT_RECRUITING	Efficacy of Amicar for Children Having Craniofacial Surgery
NCT00912119	PHASE1	COMPLETED	Amicar Pharmacokinetics of Children Having Craniofacial Surgery
NCT00077831	Not specified	COMPLETED	Child and Infant Learning Project
NCT00106977	Not specified	COMPLETED	Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)
NCT00367796	Not specified	COMPLETED	Genetic Analysis of Craniosynostosis, Philadelphia Type
NCT00769847	Not specified	WITHDRAWN	Endoscopic Treatment for Isolated, Single Suture Craniosynostosis
NCT00773643	Not specified	COMPLETED	Osteogenic Profiling of Tissue From Children With Craniosynostosis
NCT01898650	Not specified	COMPLETED	MRI for Non-invasive Evaluation of Brain Stress
NCT02287805	Not specified	COMPLETED	Qualitative and Quantitative Study Which Aims to Determine the Specifics of the Announcement for the Diagnosis of Patients With Craniosynostosis and Their Parents to Better Support Them in Their Care
NCT02561728	Not specified	WITHDRAWN	Hanger Helmet Study
NCT03025763	Not specified	ACTIVE_NOT_RECRUITING	Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones
NCT03231085	Not specified	COMPLETED	Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child
NCT04704284	Not specified	COMPLETED	Comparing MRI to CT on Pediatric Craniosynostosis.
NCT05911139	Not specified	ENROLLING_BY_INVITATION	Influence of General Anesthesia on the Dynamic Changes in Brain Damage Markers During and After Craniosynostosis Operations in Infancy
NCT06928727	Not specified	RECRUITING	Ocular Characteristics in Patients With Craniosynostosis